What aspects of antibody engineering are you interested in? In my opinion, ab-initio in silico design of novel antigen binding specificities is not yet competitive with biological production (immunization, hybridoma generation) or wet-lab selection and evolution from synthetic, naive natural or immune libraries.

Where design comes into the picture is in the reduction of immunogenicity (humanization), the improvement of stability and production yield, FC engineering to modulate effector function and the generation of multi-specific and multivalent constructs, e.g engineering the inter-chain interfaces to ensure proper pairing in producing multi-specific constructs or addition of scFv fragments to the chain to increase the number of binding sites per molecule. Antibody fragment based entities such as VHH domains and scFV can be genetically fused to other proteins as targeting modules.